99 Wall Street, Suite 232, New York, NY 10005

需要帮忙?呼叫(800) 991-3756

Class Action Cases

A class action has been filed on behalf of Nabriva Therapeutics plc Investors. Click "Join this Class Action" above.

Attorneys

(English) Nabriva Therapeutics plc

Join Class Action »

对不起,此内容只适用于美式英文

Press Release

(English) SHAREHOLDER ALERT: Zhang Investor Law Announces the Filing of a Securities Class Action Lawsuit Against Nabriva Therapeutics plc – NBRV

New York, N.Y., May 13, 2019. Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Nabriva Therapeutics plc (NASDAQ: NBRV) from November 1, 2018 through April 30, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Nabriva investors under the federal securities laws.

To join the Nabriva class action, go to http://zhanginvestorlaw.com/cases/nabriva-therapeutics-plc/ or call Sophie Zhang, Esq. or toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Nabriva’s manufacturers failed to meet good manufacturing practices; (2) these manufacturers would be subject to inspections by the U.S. Food and Drug Administration (“FDA”) in connection with Nabriva’s New Drug Application (“NDA”); (3) as a result of the manufacturing deficiencies, Nabriva’s NDA for CONTEPO was unlikely to be approved by the FDA; and (4) as a result, Nabriva’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 8, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/nabriva-therapeutics-plc/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at info@zhanginvestorlaw.com.

Zhang Investor Law represents investors worldwide.
——————————-